Supplements

When First-Line Systemic Treatment for Hepatocellular Carcinoma Fails, What Comes Next?


 

The following is a lightly edited transcript of a virtual roundtable discussion recorded in September 2020. To view the full discussion, go to www.mdedge.com/FedPrac/HCC-Roundtable.

Read More Now

Recommended Reading

Blistering Disease During the Treatment of Chronic Hepatitis C With Ledipasvir/Sofosbuvir (FULL)
Federal Practitioner
A Case-Based Review of Iron Overload With an Emphasis on Porphyria Cutanea Tarda, Hepatitis C, C282Y Heterozygosity, and Coronary Artery Disease
Federal Practitioner
Outcomes Comparison of the Veterans’ Choice Program With the Veterans Affairs Healthcare System for Hepatitis C Treatment
Federal Practitioner
HCV screening risk factors in pregnant women need updating
Federal Practitioner
Outcomes Comparison of the Veterans’ Choice Program With the Veterans Affairs Health Care System for Hepatitis C Treatment
Federal Practitioner
Retreatment of Hepatitis C Infection With Direct-Acting Antivirals
Federal Practitioner
Hep C sofosbuvir/daclatasvir combo promising for COVID-19
Federal Practitioner
New CDC guidance for health care personnel exposed to HCV
Federal Practitioner
Hepatitis screening now for all patients with cancer on therapy
Federal Practitioner
HPV-Mediated Head, Neck Cancers Predicted to Rise for Decades
Federal Practitioner